Monmouth Junction, NJ – According to filings with the U.S. Securities and Exchange Commission, Elucida Oncology is raising $35,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Geno Germano played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elucida Oncology

Elucida Oncology, Inc.is a biotechnology company focused on the development of life-changing therapeutics based on C’Dots, our novel, ultra-small cancer drug delivery platform. C’Dot-Drug-Conjugates, or CDC’s, are novel therapeutics that can substantially increase the concentration of highly potent cytotoxic drugs inside difficult to treat tumors with reduced systemic exposure due to their unique Target or Clear properties. Elucida’s breakthrough ultra-small C’Dot platform enables precise tumor targeting, deep tumor penetration and better tumor killing efficacy. Our platform enables us to produce novel therapeutics that clear rapidly and efficiently from the body, reducing the potential for off-target toxicities and resulting in an improved safety profile for patients.

To learn more about Elucida Oncology, visit http://www.elucidaoncology.com/

Contact:
Geno Germano, Chief Executive Officer
646-701-5391
ggermano@elucidaoncology.com
https://www.linkedin.com/in/geno-germano-725526131/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved